Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 59.54M P/E - EPS this Y 34.10% Ern Qtrly Grth -
Income -45.34M Forward P/E -1.24 EPS next Y 29.90% 50D Avg Chg 3.00%
Sales - PEG 0.00 EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 1.30 EPS next 5Y 116.00% 52W High Chg -73.00%
Recommedations 2.50 Quick Ratio 1.05 Shares Outstanding 39.42M 52W Low Chg 76.00%
Insider Own 2.84% ROA -57.20% Shares Float 24.78M Beta 0.27
Inst Own 48.81% ROE -208.67% Shares Shorted/Prior 1.31M/2.54M Price 1.55
Gross Margin - Profit Margin - Avg. Volume 259,204 Target Price 3.50
Oper. Margin - Earnings Date Nov 7 Volume 41,400 Change -0.64%
About Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Viracta Therapeutics, Inc. News
12/26/24 Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
11/13/24 Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/06/24 Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
09/03/24 Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08/14/24 Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
05/17/24 Viracta Therapeutics Announces New Employment Inducement Grants
05/14/24 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
05/09/24 Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
05/07/24 Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04/15/24 Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
04/01/24 Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
03/07/24 Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/29/24 Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
02/06/24 Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/04/24 Viracta Therapeutics Provides Clinical Update and Outlook for 2024
VIRX Chatroom

User Image RB818 Posted - 26 minutes from now

$VIRX Average analyst target this morning is $3.25.Buy the dip, the science will prove to be breakthrough quality.

User Image Eurydice Posted - 11 minutes ago

$VIRX πŸ˜‚

User Image Eurydice Posted - 16 minutes ago

$VIRX πŸ–•viracta

User Image Thestocktraderhubzee Posted - 3 hours ago

WATCHLIST DEC 27 2024 $ARGX argenx Gets Approval For VYVDURA In Japan To Treat Chronic Inflammatory Demyelinating Polyneuropathy Patients $VIRX Viracta Therapeutics Plans To Close Its Ongoing Pivotal Phase 2 Clinical Trial Of Nana-val In Relapsed/Refractory EBV + Lymphomas $MMLP Martin Midstream Partners Reports Termination Of Previously Announced Agreement And Plan Of Merger With Martin Resource Management $AAPL Wedbush Maintains Outperform on Apple, Raises Price Target to $325 $CELH Morgan Stanley Maintains Equal-Weight on Celsius Holdings, Maintains $42 Price Target

User Image Stmkr Posted - 7 hours ago

$VIRX Now it is becoming interesting. Cash and equivalents should be around 10M. Company has guided runway into late Q1 2025 (probably a bit longer considering news today). I think there is value in Nana-val. But can they make a deal soon enough?? Main risk is they may have to do another offering before a deal is reached.

User Image RB818 Posted - 12 hours ago

$VIRX NEWS ALERT: This is not the main trial they are running. Many of us fully expected this. It's just not the Holy Grail. Oversold on people who are really not up with what the company has working.

User Image Hiimbill Posted - 14 hours ago

$VIRX β€œViracta is making this announcement to inform shareholders and the public that the Company is engaging in discussions for strategic alternatives with the goal of maximizing value. Potential alternatives include, but are not limited to, a merger, licensing agreement, sale or other strategic transaction.” The last time this company made a similar statement, they merged within a month! Translation: sale time! πŸ’° Take your bets on what this company can fetch ? $1 billion over/under

User Image DonCorleone77 Posted - 14 hours ago

$VIRX Wow, that monthly chart (attached) is really sad: Viracta Therapeutics announces exploration of strategic alternatives Viracta Therapeutics announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas. The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding. "As we continue to look for ways to conserve resources and maximize value for the company, we made the very difficult decision to close the NAVAL-1 study while the Board undertakes its strategic review," stated Mark Rothera, President and Chief Executive Officer of Viracta. "I would like to thank the physicians and patients who participated in this important study, as well as the Viracta team members who worked so tirelessly on this program. I continue to believe that Nana-val has the potential to improve the treatment of relapsed/refractory EBV+ lymphomas, and I remain hopeful that it will one day be approved." Viracta is making this announcement to inform shareholders and the public that the company is engaging in discussions for strategic alternatives with the goal of maximizing value. Potential alternatives include, but are not limited to, a merger, licensing agreement, sale or other strategic transaction.

User Image Eurydice Posted - 14 hours ago

$VIRX is this the end?

User Image creyl Posted - 14 hours ago

$VIRX news https://viracta.investorroom.com/2024-12-26-Viracta-Therapeutics-Announces-Closure-of-NAVAL-1-Clinical-Trial-and-Exploration-of-Strategic-Alternatives

User Image Scanners_Free Posted - 15 hours ago

$VIRX NNNNNNNNNEEEEEEWWSSSSSSSSS

User Image homelessinvestorkulr Posted - 19 hours ago

$KULR $VIRX $TNXP I AM BULLISH ON KULR I AM BULLISH ON VIRX I AM BULLISH ON TNXP LFG πŸš€πŸš€πŸš€πŸš€πŸš€

User Image homelessinvestorkulr Posted - 1 day ago

$TNXP $KULR $VIRX I am very bullish on these 3 stocks Ive had major gains on all 3 and holding them long term Why settle for a few dollars when it will be worth so much more LFG πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€

User Image waeng Posted - 3 days ago

$VIRX

User Image creyl Posted - 3 days ago

$VIRX

User Image TradeJammin Posted - 3 days ago

$VIRX Bullish

User Image waeng Posted - 4 days ago

$VIRX

User Image homelessinvestorkulr Posted - 4 days ago

@iHitPredict @trigganometry dont lend your stocks as they get used to short the stock and tank the price. Anyone who understands stocks knows this The pennies they give you are not worth it as its more valuable to HOLD and reduce the shares available to short the stock $KULR $TNXP $VIRX

User Image Winning_calls Posted - 4 days ago

$VIRX pick me up @ 0.24

User Image homelessinvestorkulr Posted - 4 days ago

$VIRX is the next BIOTECH stock that will explode im 2025 πŸš€

User Image homelessinvestorkulr Posted - 5 days ago

$VIRX Viracta new cancer treatment will be a game changer in oncology πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€

User Image _Sensei_ Posted - 6 days ago

Some of our TOP plays this week! Putting out quality over quantity. Make sure to get in the discord to get my alerts first βœ‹ Enjoy your weekend folks, hope you were able to make some money on these this week $PLRZ $UK $FGL $VIRX ❀️

User Image VrtcIl Posted - 6 days ago

Let's get that 1 on $VIRX. However, make sure to keep stop set and always protect your downside. Never blindly keep on holding, let the market dictate your decisions. Price: 0.25 Float: 26.9M Short Float: 7.5 % πŸ’° Dollar Volume: 1.0K ℹ️ USA | Biotechnology

User Image _Sensei_ Posted - 6 days ago

$VIRX yessirr

User Image TradeJammin Posted - 6 days ago

$VIRX Creeper.

User Image TradeJammin Posted - 6 days ago

$VIRX I gotta have that cowbell.

User Image NoStyle79 Posted - 6 days ago

$VIRX about to start paying me

User Image NoStyle79 Posted - 1 week ago

$VIRX on watch today

User Image waeng Posted - 1 week ago

$VIRX

User Image creyl Posted - 1 week ago

$VIRX

Analyst Ratings
Leerink Partners Market Perform Aug 16, 24
RBC Capital Outperform Aug 15, 24
Oppenheimer Outperform May 23, 24
Oppenheimer Outperform Apr 17, 24
HC Wainwright & Co. Buy Apr 16, 24
HC Wainwright & Co. Buy Mar 12, 24
HC Wainwright & Co. Buy Jan 5, 24
RBC Capital Outperform Nov 10, 23
RBC Capital Outperform Oct 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rothera Mark President and CEO President and CEO Nov 30 Buy 0.49 100,000 49,000 100,000 12/04/23
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Sell 0.5 3,720 1,860 98,822 11/28/23
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Option 0 6,889 102,542 11/28/23
ROYSTON IVOR Director Director Nov 25 Option 0.00 25,219 738,865 11/28/23
Pomerantz Roger Director Director Nov 25 Option 0.00 9,034 90,341 11/28/23
ROYSTON IVOR Director Director Aug 25 Option 0.00 25,219 713,646 08/29/23
Pomerantz Roger Director Director Aug 25 Option 0.00 9,034 81,307 08/29/23
Chevallard Daniel R. CFO and COO CFO and COO Aug 25 Sell 1.45 3,512 5,092 95,653 08/29/23
Chevallard Daniel R. CFO and COO CFO and COO Aug 25 Option 0 6,888 99,165 08/29/23
ROYSTON IVOR Director Director May 25 Option 0.00 25,219 688,427 05/26/23
Pomerantz Roger Director Director May 25 Option 0.00 9,035 72,273 05/26/23
Chevallard Daniel R. CFO and COO CFO and COO May 25 Option 0 6,889 95,912 05/26/23
Chevallard Daniel R. CFO and COO CFO and COO May 25 Sell 1.42 3,635 5,162 92,277 05/26/23
ROYSTON IVOR Director Director Feb 25 Option 0.00 25,219 663,208 02/28/23
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Feb 25 Sell 1.68 2,156 3,622 48,087 02/28/23
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Feb 25 Option 0 4,127 50,243 02/28/23
Pomerantz Roger Director Director Feb 25 Option 0.00 9,034 63,238 02/28/23
Chevallard Daniel R. CFO and COO CFO and COO Feb 25 Sell 1.68 3,599 6,046 89,023 02/28/23
Chevallard Daniel R. CFO and COO CFO and COO Feb 25 Option 0 6,889 92,622 02/28/23
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Option 0 6,889 89,265 11/29/22
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Sell 2.72 3,532 9,607 85,733 11/29/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Nov 25 Option 0 4,127 48,232 11/29/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Nov 25 Sell 2.72 2,116 5,756 46,116 11/29/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Aug 25 Option 0 4,127 46,295 08/29/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Aug 25 Sell 4.01 2,190 8,782 44,105 08/29/22
Pomerantz Roger Director Director Aug 25 Option 0.00 9,034 45,170 08/29/22
Chevallard Daniel R. CFO and COO CFO and COO Aug 25 Option 0 6,889 86,031 08/29/22
Chevallard Daniel R. CFO and COO CFO and COO Aug 25 Sell 4.02 3,655 14,693 82,376 08/29/22
ROYSTON IVOR CEO & President CEO & President Aug 25 Option 0 25,219 626,149 08/29/22
ROYSTON IVOR CEO & President CEO & President Aug 25 Sell 4.01 13,379 53,650 612,770 08/29/22
ROYSTON IVOR CEO & President CEO & President May 25 Option 0 25,219 614,092 05/27/22
ROYSTON IVOR CEO & President CEO & President May 25 Sell 1.9 13,162 25,008 600,930 05/27/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer May 25 Option 0 4,127 44,322 05/27/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer May 25 Sell 1.9 2,154 4,093 42,168 05/27/22
Pomerantz Roger Director Director May 25 Option 0.00 9,034 36,136 05/27/22
Chevallard Daniel R. CFO and COO CFO and COO May 25 Option 0 6,889 82,738 05/27/22
Chevallard Daniel R. CFO and COO CFO and COO May 25 Sell 1.9 3,596 6,832 79,142 05/27/22
ROYSTON IVOR CEO & President CEO & President Feb 25 Sell 2.78 14,635 40,685 588,873 03/01/22
ROYSTON IVOR CEO & President CEO & President Feb 25 Option 0 25,219 603,508 03/01/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Feb 25 Option 0 4,127 42,590 03/01/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Feb 25 Sell 2.78 2,395 6,658 40,195 03/01/22
Pomerantz Roger Director Director Feb 25 Option 0.00 9,034 27,102 03/01/22
Chevallard Daniel R. CFO and COO CFO and COO Feb 25 Option 0 6,889 79,847 03/01/22
Chevallard Daniel R. CFO and COO CFO and COO Feb 25 Sell 2.78 3,998 11,114 75,849 03/01/22
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Nov 25 Option 0 8,254 43,004 11/29/21
Rojkjaer Lisa Chief Medical Office.. Chief Medical Officer Nov 25 Sell 4.81 4,541 21,842 38,463 11/29/21
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Option 0 13,777 80,537 11/29/21
Chevallard Daniel R. CFO and COO CFO and COO Nov 25 Sell 4.81 7,579 36,455 72,958 11/29/21
ROYSTON IVOR CEO & President CEO & President Nov 25 Option 0 50,437 599,036 11/29/21
ROYSTON IVOR CEO & President CEO & President Nov 25 Sell 4.81 27,747 133,463 571,289 11/29/21